Efficacy of AST‐120 in Dogs with Chronic Idiopathic Enteropathies. (15th October 2013)

• Record Type: Journal Article
• Authors: Volkmann, M.; Wirtherle, N.C.; Beddies, G.F.; Kohn, B.
• Is Part Of: Journal of veterinary internal medicine. Volume 27:Number 6(2013:Nov./Dec.)
• Page Start: 1637
• Page End: 1641
• Publication Date: 2013-10-15
• Subjects: Veterinary medicine -- Periodicals; 636.0896
• DOI: 10.1111/jvim.12212
• Languages: English
• ISSNs: 0891-6640

Abstract

<abstract abstract-type="main" id="jvim12212-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jvim12212-sec-0001" sec-type="section"> <title>Background</title> <p>Chronic idiopathic enteropathies (CIE) in dogs are complex diseases of unknown origin. AST‐120 is a spherical carbon adsorbent preparation with a high adsorption ability for low molecular substances.</p> </sec> <sec id="jvim12212-sec-0002" sec-type="section"> <title>Objectives</title> <p>Evaluation of the clinical efficacy of AST‐120 in dogs with CIE.</p> </sec> <sec id="jvim12212-sec-0003" sec-type="section"> <title>Animals</title> <p>Ten client‐owned dogs with mild (n = 7) to moderate (n = 3) CIE.</p> </sec> <sec id="jvim12212-sec-0004" sec-type="section"> <title>Methods</title> <p>Explorative, prospective, randomized, placebo‐controlled, double‐blinded pilot study. Dogs with chronic diarrhea and no or insufficient response to an elimination diet were included. The dogs received either AST‐120 (n = 5) or placebo (n = 5) for a duration of 21 days. The canine inflammatory bowel disease activity index (CIBDAI) was used to assess disease severity at baseline and clinical outcome after 3 weeks of treatment. Furthermore, changes in body weight and the parameters stool consistency and frequency were compared within and between groups.</p> </sec> <sec id="jvim12212-sec-0005" sec-type="section"> <title>Results</title> <p>The mean CIBDAI score decreased from 5.6 (SD 1.5) to 2.0 (SD 1.2) in the AST‐120 group (<italic>P</italic> = .125) and from 4.8 (SD .8) to 3.6 (SD 2.3) in the placebo group (<italic>P</italic> = .688). Compared with baseline, posttreatment CIBDAI scores decreased more than 60% in 4/5 dogs treated with AST‐120 and in 1/5 dogs treated with placebo (<italic>P</italic> = .206). Changes in CIBDAI scores, body weights, stool consistency, and frequency within and between groups did not achieve statistical significance after 3 weeks of treatment. No adverse effects of AST‐120 were noted.</p> </sec> <sec id="jvim12212-sec-0006" sec-type="section"> <title>Conclusions and Clinical Importance</title> <p>This study investigated potential efficacy of AST‐120 as an alternative therapy in dogs with mild‐to‐moderate CIE.</p> </sec> </abstract>